Skip to main content Skip to section navigation Skip to footer
Investors & Media Clinical Trials Careers Contact Us
Facebook link Twitter link Linkedin link
CymaBay Therapeutics
  • Home
  • Our Company
    • Overview
    • Leadership Team
    • Board of Directors
  • Our Purpose
    • Overview
    • About Liver Disease
    • About PBC
    • Patient Advocacy
    • Patient Resources
    • Grants & Giving
    • Expanded Access
  • Our Science
    • Overview
    • Unmet Needs in PBC
    • Seladelpar
    • MBX-2982
    • Collaborations
  • Investors & Media
  • Clinical Trials
  • Careers
  • Contact Us

Publications

Investors & Media

Investors & Media

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Presentations
    • Publications
    • Email Alerts
  • Company Info
    • Overview
    • Leadership Team
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Presentations
  • Publications
  • Email Alerts

Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study

A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis

Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis

Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study

The selective peroxisome proliferator-activated receptor-delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice

A pilot study of MBX-8025 in the treatment of homozygous familial hypercholesterolemia (HoFH)

MBX-8025, A Novel Peroxisome Proliferator Receptor-Agonist: Lipid and Other Metabolic Effects in Dyslipidemic Overweight Patients Treated with and without Atorvastatin

Effects of the PPAR-δ agonist MBX-8025 on atherogenic dyslipidemia

rss_feed RSS
  • Email Alerts
  • Company Profile
  • Contacts
  • RSS News Feed
©2023 CymaBay Therapeutics. All Rights Reserved.
Privacy Policy Disclaimer Sitemap Manage Cookie Preferences
Facebook link Twitter link Linkedin link

You are leaving our website!

Continue